西酞普兰联合舒肝解郁胶囊治疗重度抑郁症的临床疗效研究

Clinical Study of Citalopram Combined With Shuganjieyu Capsule in Treating Major Depressive Disorder

目的 探讨西酞普兰联合舒肝解郁胶囊治疗重度抑郁症的临床疗效。方法 回顾性分析2015年1月~2016年5月我院收治的86例重度抑郁症患者的临床资料,将其按照治疗方法分为两组,研究组和对照组各43例,研究组用西酞普兰联合舒肝解郁胶囊治疗,对照组单独应用西酞普兰治疗,连续治疗6周,比较HAMD、HAMA评分及临床疗效。结果 治疗后两组HAMD、HAMA评分均较治疗前降低,差异有统计学意义（P〈0.05）;治疗后研究组HAMD、HAMA评分与对照组比较更低,两组差异有统计学意义（P〈0.05）。研究组的总有效率与对照组比较更高,两组差异有统计学意义（P〈0.05）。结论 重度抑郁症患者使用西酞普兰联合舒肝解郁胶囊治疗效果较好,能有效改善患者的临床症状体征,效果优于单独应用西酞普兰治疗。

Objective To investigate the clinical efficacy of citalopram combined with shuganjieyu capsule in the treatment of severe depression. Methods The clinical data of 86 patients with severe depression treated in our hospital from January 2（115 to May 2016 were retrospectively analyzed. The patients were divided into two groups according to the treatment methods. The study group and the control group had 43 cases. The study group was .given citalopram combined with shuganjieyu capsule, the control group was treated with citalopram alone, continuous treatment for 6 weeks, HAMD, HAMA score and clinical efficacy of two groups were compared, Results After treatment, HAMD and HAMA scores of the two groups were significantly lower than those before treatment （P 〈 0.05 ） . The scores of HAMD and HAMA in study group were lower than the control group, there was significant difference between two groups （ P 〈 0.05 ） . The total effective rate of the study group was higher than that of the control group, the difference was statistically significant （ P 〈 0.05 ） . Conclusion Citalopram combined with shuganjieyu capsule is effective in improving the clinical symptoms and signs of patients with severe depression. The effect is better than that ofcitalopram alone.